IXICO (IXI) Share Price, News & Analysis

Company Overview

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, the company focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, and orphan and rare diseases. Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

Key Stats

• Today's Range: 12.21 to 13
• 50-Day Range: 8.25 to 12.97
• 52-Week Range: 6.35 to 15.48
• Volume: 364,427 shs
• Average Volume: 71,545 shs
• Market Capitalization: £6.16 million
• P/E Ratio: N/A
• Dividend Yield: 1.27%
• Price Target: N/A
• Consensus Rating: N/A

IXI Stock Analysis - Frequently Asked Questions

How have IXI shares performed this year?

IXICO's stock was trading at GBX 12.50 at the beginning of 2024. Since then, IXI stock has increased by 2.0% and is now trading at GBX 12.75.
View the best growth stocks for 2024 here.

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) posted its earnings results on Wednesday, May, 20th. The company reported $1.01 earnings per share for the quarter. IXICO had a negative net margin of 31.10% and a negative trailing twelve-month return on equity of 16.99%.

How do I buy shares of IXICO?

Shares of IXI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IXICO investors own include BioNTech (BNTX), Benefitfocus (BNFT), Grayscale Bitcoin Trust (GBTC), Motif Bio (MTFB), Pfizer (PFE), Tesla (TSLA) and VEON (VEON).

Company Calendar

• Last Earnings: 5/20/2020
• Today: 11/24/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:IXI
• CUSIP: N/A
• CIK: N/A
• Web: ixico.com
• Phone: +44-20-37637499
• Fax: N/A
• Employees: 89
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.38
• Net Income: £-1,870,000.00
• Net Margins: -31.10%
• Pretax Margin: N/A
• Return on Equity: -16.99%
• Return on Assets: -10.40%

Debt

• Debt-to-Equity Ratio: 3.22
• Current Ratio: 3.64
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: £6 million
• Price / Sales: 1.03
• Cash Flow: GBX 5.67 per share
• Price / Cash Flow: 2.25
• Book Value: GBX 21 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 48,350,000
• Free Float: N/A
• Market Cap: £6.16 million
• Optionable: Not Optionable
• Beta: 0.86